Incorporating New Medications in Diabetes Care
Authors: Richard J. Comi
Journal: Annals of Internal Medicine (2015)

Editorials3 November 2015Incorporating New Medications in Diabetes CareRichard J. Comi, MDRichard J. Comi, MDFrom Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-2179 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Keeping up with the rapidly expanding options for the pharmacologic management of type 2 diabetes is difficult for clinicians. In contrast to the 1960s, when the only treatments available were 2 kinds of insulin and sulfonylureas, there are now at least 3 classes of insulin and 6 effective noninsulin classes of medications. Strategies for deploying these medications remain in evolution, if not turmoil, because each agent has its own pattern of effectiveness, adverse effects, pharmacokinetics, costs, and drug interactions. Older clinicians may recall the dilemma that the UGDP (University Group Diabetes Program) study posed in the 1970s when it suggested ...References1. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes. 1972;21:976-9. [PMID: 5055722] CrossrefMedlineGoogle Scholar2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. [PMID: 18256393] doi:10.1056/NEJMoa0706245 CrossrefMedlineGoogle Scholar3. Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med. 2015;163:663-72. doi:10.7326/M15-0308 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-2179.Corresponding Author: Richard J. Comi, MD, Section Chief, Section of Endocrinology and Metabolism, Dartmouth Hitchcock Medical Center, Hitchcock Clinic, One Medical Center Drive, Lebanon, NH 03756.This article was published online first at www.annals.org on 13 October 2015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus Shuo-Ming Ou , Chia-Jen Shih , Pei-Wen Chao , Hsi Chu , Shu-Chen Kuo , Yi-Jung Lee , Shuu-Jiun Wang , Chih-Yu Yang , Chih-Ching Lin , Tzeng-Ji Chen , Der-Cherng Tarng , Szu-Yuan Li , and Yung-Tai Chen Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus Shuo-Ming Ou , Chia-Jen Shih , Pei-Wen Chao , Hsi Chu , Shu-Chen Kuo , Yi-Jung Lee , Shuu-Jiun Wang , Chih-Yu Yang , Chih-Ching Lin , Tzeng-Ji Chen , Der-Cherng Tarng , Szu-Yuan Li , and Yung-Tai Chen Metrics 3 November 2015Volume 163, Issue 9Page: 719-720KeywordsAdverse eventsDisclosureEndocrinologyFactor analysisGlucoseHemoglobinInsulinInsulin-like growth factorsType 2 diabetes ePublished: 13 October 2015 Issue Published: 3 November 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...